KYV-101 + Standard lymphodepletion regimen
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Sclerosis
Conditions
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Trial Timeline
Aug 6, 2024 → Mar 1, 2027
NCT ID
NCT06400303About KYV-101 + Standard lymphodepletion regimen
KYV-101 + Standard lymphodepletion regimen is a phase 1/2 stage product being developed by Kyverna Therapeutics for Systemic Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT06400303. Target conditions include Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06400303 | Phase 1/2 | Active |
Competing Products
20 competing products in Systemic Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |
Other Products from Kyverna Therapeutics
Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101Phase 2/3
57
Standard lymphodepletion regimenPhase 2
44
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mABPhase 2
44
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyPhase 1/2
33
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimenPhase 1/2
33